Co-Diagnostics Inc is a biotechnology company that focuses on the development and manufacturing of molecular diagnostic tests used to detect diseases
The company specializes in the design of innovative testing solutions that leverage its proprietary technologies for amplification and detection of nucleic acids. Co-Diagnostics aims to provide accurate and timely diagnostic tools that facilitate the identification of various pathogens, aiding in disease prevention and management. Through its commitment to enhancing diagnostic capabilities, the company supports healthcare providers and public health initiatives.
In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday.
San Diego, CA -- (SBWIRE) -- 11/18/2022 -- Certain directors of Co-Diagnostics, Inc are under investigation over potential breaches of fiduciary duties.
Co-Diagnostics (NASDAQCODX) is set to give its latest quarterly earnings report on Thursday, 2022-11-10. Here's what investors need to know before the announcement. Analysts estimate that Co-Diagnostics will report an earnings per share (EPS) of $-0.04.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Co-Diagnostics, Inc. (“Co-Dx” or the “Company”) (NASDAQCODX) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Co-Dx securities between May 12, 2022 and August 11, 2022, both dates inclusive (the “Class Period”). Investors have until October 17, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
